| NASDAQ (usa) |   | 6715.56 | -12.11 | -0.18% | 
| FTSE 100 (london) |  | 7487.96 | -5.12 | -0.07% | 
| DAX (german) |   | 13465.51 | 235.94 | 1.78% | 
| NIKKEI 225 (japan) |   | 22420.08 | 408.47 | 1.86% | 
| Hang - Seng (hong kong) |   | 28594.06 | 348.52 | 1.23% | 
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |   | 3391.61 | 17.53 | 0.52% | 
| KOSPI (korea) |   | 2556.47 | 33.04 | 1.31% | 
| All Ordinaries (australia) |   | 6005.30 | 28.90 | 0.48% | 
| BOVESPA (brazil) |   | 74092.76 | -215.73 | -0.29% | 
Lytix Biopharma AS (OL: LYTIX)
                                    	LYTIX Technical Analysis
                                    
                                    
    1.5
    
    
    
    
									| As on 30th Oct 2025 LYTIX STOCK Price closed @ 7.76 and we RECOMMEND Buy for LONG-TERM with Stoploss of 7.01 & Sell for SHORT-TERM with Stoploss of 8.06 we also expect STOCK to react on Following IMPORTANT LEVELS. | 
LYTIXSTOCK Price
| Open | 7.32 | Change | Price | % | 
| High | 7.96 | 1 Day | -0.24 | -3.00 | 
| Low | 7.32 | 1 Week | -0.02 | -0.26 | 
| Close | 7.76 | 1 Month | 0.74 | 10.54 | 
| Volume | 66960 | 1 Year | 2.36 | 43.70 | 
| 52 Week High 12.25 | 52 Week Low 4.76 | ||||
    OL Norway Most Active Stocks
                    | AGAS | 0.24 | 71.43% | 
| AKH | 0.44 | -29.03% | 
| BORR | 40.56 | 0.00% | 
| AOW | 2.00 | -5.21% | 
| NHY | 67.26 | -2.32% | 
| KOG | 241.20 | -18.25% | 
| NAS | 15.60 | 2.36% | 
| HUNT | 1.52 | 4.83% | 
| NEL | 2.30 | 0.00% | 
| NODL | 0.23 | -11.54% | 
OL Norway Top Gainers Stocks
                    
                OL Norway Top Losers Stocks
                    
                | LYTIX Daily Charts | LYTIX Intraday Charts | Whats New @ Bazaartrend | LYTIX Free Analysis | 
|  | 
LYTIX Important Levels Intraday
                                    | RESISTANCE | 8.99 | 
| RESISTANCE | 8.60 | 
| RESISTANCE | 8.35 | 
| RESISTANCE | 8.11 | 
| SUPPORT | 7.41 | 
| SUPPORT | 7.17 | 
| SUPPORT | 6.92 | 
| SUPPORT | 6.53 | 
LYTIX Forecast  October 2025
                                    | 4th UP Forecast | 14.5 | 
| 3rd UP Forecast | 12.34 | 
| 2nd UP Forecast | 11 | 
| 1st UP Forecast | 9.67 | 
| 1st DOWN Forecast | 5.85 | 
| 2nd DOWN Forecast | 4.52 | 
| 3rd DOWN Forecast | 3.18 | 
| 4th DOWN Forecast | 1.02 | 
     LYTIX Weekly Forecast
                                    
                                    
                                | 4th UP Forecast | 12.85 | 
| 3rd UP Forecast | 11.22 | 
| 2nd UP Forecast | 10.21 | 
| 1st UP Forecast | 9.20 | 
| 1st DOWN Forecast | 6.32 | 
| 2nd DOWN Forecast | 5.31 | 
| 3rd DOWN Forecast | 4.30 | 
| 4th DOWN Forecast | 2.67 | 
LYTIX Forecast2025
                                    | 4th UP Forecast | 27.9 | 
| 3rd UP Forecast | 21.44 | 
| 2nd UP Forecast | 17.45 | 
| 1st UP Forecast | 13.46 | 
| 1st DOWN Forecast | 2.06 | 
| 2nd DOWN Forecast | -1.93 | 
| 3rd DOWN Forecast | -5.92 | 
| 4th DOWN Forecast | -12.38 | 
                                        Lytix Biopharma AS ( OL Norway Symbol : LYTIX ) 
Sector : Healthcare And Other Stocks in Same Sector
                                    
                                    
                                Sector : Healthcare And Other Stocks in Same Sector
LYTIX Other Details
                    | Segment | EQ | |
| Market Capital | 519102592.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
LYTIX Address
                                 |  | ||
                                        LYTIX Latest News
                                    
                                    
                                    LYTIX Business Profile
   
	 Lytix Biopharma ASA, a clinical stage biotech company, engages in the research and development of medicines for cancer indications based on immunotherapy in Norway. Its lead product candidate is LTX-315, an oncolytic peptide with potent immunomodulatory properties, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic pipeline product, is a low-molecular drug that is designed for deep-seated visceral tumors and is in a preclinical phase. The company was founded in 2003 and is based in Oslo, Norway. Address: Hoffsveien 4, Oslo, Norway, 0275 
	
            
            © 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
 
	   Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

